Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure
|
|
- Sherman Richard
- 6 years ago
- Views:
Transcription
1 Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure Joseph S. Van Tuyl, Pharm.D. PGY1 Pharmacy Resident The University of Oklahoma College of Pharmacy April 4, 2014
2 Disclosures No conflicts of interest. 2
3 Objectives 1. Describe the impact of lack of potassium replacement guidelines in patients with CVD. 2. Describe the relationship of patient characteristics on the incidence of hypokalemia in ACS and ADHF. CVD = Cardiovascular disease ACS = Acute coronary syndromes ADHF = Acute decompensated heart failure 3
4 Potassium Homeostasis Gennari FJ. N Engl J Med 1998; 339 (7):
5 Causes of Hypokalemia Comorbidities Aldosteronism Cushing s syndrome Bartter syndrome Liddle syndrome Hypomagnesemia Diarrhea Vomiting Medications Diuretics Mineralocorticoids Glucocorticoids β 2 -adrenergic agonists Aminoglycosides Amphotericin B Cohn JN, et al. Arch Intern Med 2000; 160:
6 Potassium Replacement Guidelines Strategies to achieve/maintain normokalemia must consider: Baseline potassium values Underlying medical conditions Medications Diet and salt intake Adherence to therapeutic regimen Lack specific recommendations and goals Cohn JN, et al. Arch Intern Med 2000; 160:
7 Significance in CVD Predisposition to hypokalemia Neuroendocrine response Sympathetic nervous system Renin-angiotensin-aldosterone system Medications altering serum potassium Predisposition to arrhythmias Macdonald JE, et al. J Am Coll Cardiol 2004; 43:
8 Potassium Goals in CVD Disorder Goal (meq/l) Reason Acute Myocardial Infarction ventricular arrhythmias Heart Failure ventricular arrhythmias QT and QT d Improve prognosis Macdonald JE, et al. J Am Coll Cardiol 2004; 43:
9 Evolving Potassium Goals 70 In-Hospital Mortality According to Serum Potassium in AMI Mortality (%) < < < < < < Serum Potassium Goyal A, et al. JAMA 2012; 307(2):
10 Implications for Patient Care Potassium homeostasis is multifactorial Current recommendations are non-specific and evolving Recommendations for potassium replacement may not reflect needs of patients with CVD Suboptimal potassium replacement Increased risk of arrhythmias Increased risk of mortality 10
11 Study Site OU Medical Center Presbyterian OUHSC campus Academic medical center Total 325 beds CCU 30 beds 11
12 Methods Retrospective, descriptive study Inclusion Criteria Admission from July 31, 2010 to July 31, years of age Principal admission diagnosis Unstable angina Non-ST elevation myocardial infarction ST-elevation myocardial infarction Acute decompensated heart failure Exclusion Criteria <18 years of age Cushing s/addison s disease Corticosteroid use Illicit drug use 12
13 Methods Primary Objective Incidence of hypokalemia (K+ <3.5 meq/l) Descriptive statistics Demographics Age Gender Ethnicity Comorbidities Charlson comorbidity index score Renal function (Cockcroft-Gault creatinine clearance) Medications 13
14 Methods Secondary Objective Describe the relationship of the following variables on the incidence of hypokalemia: Principal admission diagnosis Age Gender Ethnicity Renal function Charlson comorbidity index score Medications β-adrenergic antagonists, RAAS antagonists, diuretics Multiple linear regression (α = 0.05) 14
15 Preliminary Results 35% Incidence of Hypokalemia (K+ <3.5 meq/l) 30% 25% 20% 15% 10% 5% 0% USA NSTEMI STEMI ADHF 15
16 Conclusions Risk of developing hypokalemia ACS vs. ADHF Comorbidities Renal function Medications Potassium replacement protocol Individualized to patients with ACS and ADHF 16
17 Assessment Questions Which of the following is a consequence of hypokalemia? A. Hypotension B. Arrhythmias C. Angina D. Hypervolemia 17
18 Assessment Questions Which of the following predisposes patients to the development of hypokalemia? A. Cushing s syndrome B. Addison s disease C. Hypermagnesemia D. Renin-angiotensin-aldosterone antagonism 18
19 Acknowledgements Toni L. Ripley, Pharm.D., FCCP, BCPS (AQ-Cardiology) Holly R. Herring, Pharm.D., BCPS Jamie L. Miller, Pharm.D., BCPS Kevin Farmer, Ph.D. 19
20 Hypokalemia in Acute Coronary Syndromes and Acute Decompensated Heart Failure Joseph S. Van Tuyl, Pharm.D. PGY1 Pharmacy Resident The University of Oklahoma College of Pharmacy April 4, 2014
Heart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationPP-US-DSE Relypsa, Inc. All rights reserved. Relypsa and the Relypsa logo are trademarks of Relypsa, Inc.
1 2 There are 4 main objectives that I d like to cover with you today: First, to review the definition, prevalence, and risk of hyperkalemia in certain populations Second, to review why RAASi are recommended
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationCardiology Pharmacist. Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018
Cardiology Pharmacist Melanie Madorsky, PharmD, BCPS TSHP Annual Meeting April 7, 2018 Melanie.Madorsky@memorialhermann.org Objectives Explain the daily responsibilities of the Cardiology Pharmacist Identify
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationSerum potassium levels and outcomes in critically ill patients in the medical intensive care unit
Clinical Report Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit Journal of International Medical Research 2018, Vol. 46(3) 1254 1262! The Author(s) 2018
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationDigoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure Effect of mild moderate renal impairment
Journal of Clinical Epidemiology 56 (2003) 646 650 Digoxin therapy and the risk of primary cardiac arrest in patients with congestive heart failure Effect of mild moderate renal impairment Thomas D. Rea
More informationPotassium Abnormalities in Current Clinical Practice: Frequency, Causes, Severity and Management
Original Paper Received: August 4, 2014 Accepted: January 29, 2015 Published online: March 11, 2015 Potassium Abnormalities in Current Clinical Practice: Frequency, Causes, Severity and Management Eylem
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationPrescriber Training Slide Deck
Prescriber Training Slide Deck 1 Contents Introduction CAPRELSA (vandetinib) Tablets Indication Risk of QT Prolongation, Torsades de pointes, and Sudden Death Patient Selection ECG and Electrolyte Monitoring
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationA Study of Potassium Dip and Severity of Acute Ischemic Stress In Patients with Acute Coronary Syndrome
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. I (June. 2017), PP 01-10 www.iosrjournals.org A Study of Potassium Dip and Severity
More informationkeyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests
www.bpac.org.nz keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests Why do we monitor patients taking diuretics and what do we monitor? Monitoring a person on
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationCAPRELSA (vandetanib) Tablets and Risk of QT Prolongation, Torsades de Pointes and Sudden Death
CAPRELSA (vandetanib) Tablets and Risk of QT Prolongation, Torsades de Pointes and Sudden Death Prescriber Training Pamphlet Introduction This training pamphlet has been developed as part of a REMS program
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationEvidence-based Appraisal of the FOURIER Trial
evidence-based practice Evidence-based Appraisal of the FOURIER Trial Citation: Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationConflict of interest
Hyperkalemia in Heart and Kidney patients: Rescue is here Wajeh Qunibi, MD, FACP Professor of Medicine University of Texas Health Science Center San Antonio, TX CARDIORENAL CONNECTION April 28, 2017 Conflict
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More information5/18/2017. Specific Electrolytes. Sodium. Sodium. Sodium. Sodium. Sodium
Specific Electrolytes Hyponatremia Hypervolemic Replacing water (not electrolytes) after perspiration Freshwater near-drowning Syndrome of Inappropriate ADH Secretion (SIADH) Hypovolemic GI disease (decreased
More informationValsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University
Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension
More informationWhat s all the Fuss?
HYPERTENSION: What s all the Fuss? Presenter name: Presenter title: Department: Institute Marc A. Pohl, MD Ray W. Gifford Chair in Hypertension, and Head, Section of Clinical Hypertension Nephrology and
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationHeart Failure Pharmacotherapy An Update
Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF
More information12/19/16. Disclosures
@atriumrx Don t Miss a Beat! Practical Tips on Managing Drug-Induced QTc Prolongation Sandeep Devabhakthuni, PharmD, BCPS- AQ Cardiology Assistant Professor University of Maryland School of Pharmacy Disclosures
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationPotassium as a Treatable Biomarker in Cardiovascular Disease: New Keys to Hyperkalemia
Potassium as a Treatable Biomarker in Cardiovascular Disease: New Keys to Hyperkalemia Nicholas Wettersten, MD Associate Professor Heart Failure, Mechanical Circulatory Support and Transplant March 1 st,
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: An update on the changing recommendations for treating hypertension New trial data and guidelines have made hypertension care more
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationSupplementary figures and tables. Figure A: Study schematic
Supplementary figures and tables Figure A: Study schematic Figure B: Percent of patients with a normal (green), borderline (beige), abnormal (brown), or high (red) electrocardiogram 14-90 days after prescription
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationPreoperative tests (update)
National Institute for Health and Care Excellence. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix C: April 2016 Developed by the National Guideline
More informationHYPERKALEMIA. Best Practices in Managing. in Chronic Kidney Disease
+ Best Practices in Managing HYPERKALEMIA in Chronic Kidney Disease Hyperkalemia in Chronic Kidney Disease (CKD) Treatment with RAAS Inhibitors (RAASi) in CKD Diagnosis and Evaluation of Hyperkalemia Treatment
More informationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2015.10.037
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationPotassium regulation. -Kidney is a major regulator for potassium Homeostasis.
Potassium regulation. -Kidney is a major regulator for potassium Homeostasis. Normal potassium intake, distribution, and output from the body. Effects of severe hyperkalemia Partial depolarization of cell
More informationA case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY
A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY Case 57 y.o. male CC: Weakness HPI: About 20 years ago, he developed bilateral lower extremity weakness. Laboratory
More informationJournal of the American College of Cardiology Vol. 45, No. 11, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 11, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.02.068
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationInformRx. Managing Chronic Hyperkalemia. By Pam Scandrett, R.Ph. Risks of High Potassium Levels CLINICAL & REGULATORY NEWS BY PHARMERICA
Managing Chronic Hyperkalemia By Pam Scandrett, R.Ph. CLINICAL & REGULATORY NEWS BY PHARMERICA JAN/FEB 2019 Potassium (K+) is found inside skeletal muscle, liver, and red blood cells. Normal levels of
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationElectrolyte Imbalance and Resuscitation. Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine
Electrolyte Imbalance and Resuscitation Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine Presentation plan Definition of the electrolyte disturbances Conditions
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationRole of Aldosterone Antagonists in the Current Management of Heart Failure
Role of Aldosterone Antagonists in the Current Management of Heart Failure Yabluchansky, Nykola Chronic heart failure (HF) is one of the most important syndromes in cardiology. Their main causes are: ischemic
More informationNatriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives
Natriuretic peptides and cardiovascular diseases: from old concepts to novel perspectives Speranza Rubattu, M.D. School of Medicine and Psychology, Sapienza University, Rome, Italy Natriuretic peptides
More informationIntegrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure
Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated
More informationHow to Manage Resistant Hypertension Min Su Hyon, MD
How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine Definition Resistant to conventional medical therapy Definition
More informationIntroduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP
Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level
More informationClinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationHeart Failure Clinic: A Multidisciplinary Approach
Heart Failure Clinic: A Multidisciplinary Approach Deborah Caraballo, RPh, PharmD, PhC, BCPS-Cardiology Wilson Cardiology Lecture September 16 th, 2017 ALLPPT.com _ Free PowerPoint Templates, Diagrams
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 1. To highlight the link between AKI and progression to CKD 2. To discuss the newer agents that have come available for the treatment of hyperkalemia
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationPrevention of Cardiovascular Events in Hypertension and CAD & Management of Hypertension in HF of Ischemic origin
"Insight Heart" is also available at www.squarepharma.com.bd Vol: 911 No: 4; 4; 2012 2015 Prevention of Cardiovascular Events in Hypertension and CAD Drug-eluting & Management of Hypertension in HF of
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationPreliminary Programme
Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management
More informationObjectives. Pathophysiology of Steroids. Question 1. Pathophysiology 3/1/2010. Steroids in Septic Shock: An Update
Objectives : An Update Michael W. Perry PharmD, BCPS PGY2 Critical Care Resident Palmetto Health Richland Hospital Review the history of steroids in sepsis Summarize the current guidelines for steroids
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More information